Revenue Breakdown
Composition ()
No data
Revenue Streams
ImmuCell Corp (ICCC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is First Defense® product line, accounting for 99.3% of total sales, equivalent to $6.40M. Another important revenue stream is Other animal health. Understanding this composition is critical for investors evaluating how ICCC navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, ImmuCell Corp maintains a gross margin of 42.92%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.36%, while the net margin is -2.54%. These profitability ratios, combined with a Return on Equity (ROE) of 8.27%, provide a clear picture of how effectively ICCC converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ICCC competes directly with industry leaders such as INKT and LONA. With a market capitalization of $57.62M, it holds a leading position in the sector. When comparing efficiency, ICCC's gross margin of 42.92% stands against INKT's N/A and LONA's N/A. Such benchmarking helps identify whether ImmuCell Corp is trading at a premium or discount relative to its financial performance.
